Study Description (For Patients, Families, and Healthcare Providers)
Purpose:
The aim of this study is to evaluate the effectiveness and safety of methotrexate treatment in women with ectopic pregnancy who belong to a group for whom this treatment is relatively contraindicated.
Background:
Methotrexate is a medication commonly used in the treatment of ectopic pregnancy (a pregnancy that occurs outside the uterus, usually in the fallopian tube). However, in certain conditions - such as kidney or liver dysfunction - methotrexate use may carry increased risks. These situations are known as relative contraindications. This study will retrospectively examine treatment outcomes in this specific patient population.
Method:
The study will analyze medical records of patients who were previously treated with methotrexate for ectopic pregnancy. No new interventions will be performed. The analysis will be based solely on existing clinical data.
Why Is This Important? The findings of this study may help us better understand the safety limits of methotrexate therapy and guide healthcare providers in managing similar cases in the future.
Diagnosed with ectopic pregnancy
Received methotrexate (MTX) treatment
Underwent surgical treatment due to lack of response to MTX therapy
Compliant with treatment follow-up
Participants with contraindications to methotrexate (MTX) treatment
Participants non-compliant with follow-up
Patients diagnosed with ectopic pregnancy and treated with methotrexate
Case-control
Retrospective
Drug: Methotrexate (MTX) Patients received methotrexate treatment according to institutional protocols. Dosage and administration routes were recorded retrospectively. For patients who did not respond
DrugMTX medical treatment Laparoscopic salpingectomy Laparoscopic salpingostomy
Change in serum β-hCG levels (IU/L)
Serum beta-human chorionic gonadotropin levels measured via blood test on days 0, 4, and 7 of methotrexate treatment.
Hospital stay duration (days)
Number of days each patient remained hospitalized from treatment initiation to discharge.
endometrial thickness (mm), ectopic focus size (mm), and douglas pouch fluid (mm)
Measured via transvaginal ultrasound at diagnosis.
Click on the lead sponsor to view all of their trials.
